# Object Record 3
**objectId:** dashboard-item-1759906246155-lab-table
**type:** component
**componentType:** LabTable
**description:** 
**content title:** Lab Findings
**content component:** LabTable
**content props encounters 0 encounter no:** 1
**content props encounters 0 date:** 2015-08-10
**content props encounters 0 meta ui risk color:** green
**content props encounters 1 encounter no:** 2
**content props encounters 1 date:** 2016-02-20
**content props encounters 1 meta ui risk color:** green
**content props encounters 2 encounter no:** 3
**content props encounters 2 date:** 2018-09-05
**content props encounters 2 meta ui risk color:** green
**content props encounters 3 encounter no:** 4
**content props encounters 3 date:** 2021-03-15
**content props encounters 3 meta ui risk color:** green
**content props encounters 4 encounter no:** 5
**content props encounters 4 date:** 2025-06-15
**content props encounters 4 meta ui risk color:** amber
**content props encounters 5 encounter no:** 6
**content props encounters 5 date:** 2025-06-21
**content props encounters 5 meta ui risk color:** red
**content props encounters 5 meta event tags 0:** Suspected DILI
**content props encounters 5 meta event tags 1:** Potential MTX toxicity
**content props encounters 5 meta event tags 2:** Acute liver failure risk
**createdAt:** 2025-10-14T16:50:46.155Z
**updatedAt:** 2025-10-14T16:50:46.155Z

# Object Record 4
**objectId:** dashboard-item-1759906246156-lab-chart
**type:** component
**componentType:** LabChart
**description:** 
**content title:** Lab Trends
**content component:** LabChart
**content props encounters 0 encounter no:** 1
**content props encounters 0 date:** 2015-08-10
**content props encounters 0 meta ui risk color:** green
**content props encounters 1 encounter no:** 2
**content props encounters 1 date:** 2016-02-20
**content props encounters 1 meta ui risk color:** green
**content props encounters 2 encounter no:** 3
**content props encounters 2 date:** 2018-09-05
**content props encounters 2 meta ui risk color:** green
**content props encounters 3 encounter no:** 4
**content props encounters 3 date:** 2021-03-15
**content props encounters 3 meta ui risk color:** green
**content props encounters 4 encounter no:** 5
**content props encounters 4 date:** 2025-06-15
**content props encounters 4 meta ui risk color:** amber
**content props encounters 5 encounter no:** 6
**content props encounters 5 date:** 2025-06-21
**content props encounters 5 meta ui risk color:** red
**content props encounters 5 meta event tags 0:** Suspected DILI
**content props encounters 5 meta event tags 1:** Potential MTX toxicity
**content props medicationTimeline 0 name:** Methotrexate
**content props medicationTimeline 0 start:** 2015-08-10
**content props medicationTimeline 0 dose:** 10mg weekly
**content props medicationTimeline 1 name:** Methotrexate
**content props medicationTimeline 1 start:** 2018-09-05
**content props medicationTimeline 1 dose:** 20mg weekly
**content props medicationTimeline 2 name:** Lisinopril
**content props medicationTimeline 2 start:** 2018-09-05
**content props medicationTimeline 2 dose:** 10mg daily
**content props medicationTimeline 3 name:** Trimethoprim-Sulfamethoxazole
**content props medicationTimeline 3 start:** 2025-06-15
**content props medicationTimeline 3 end:** 2025-06-25
**content props medicationTimeline 3 dose:** 800/160mg BID
**createdAt:** 2025-10-14T16:50:46.156Z
**updatedAt:** 2025-10-14T16:50:46.156Z

# Object Record 2
**objectId:** dashboard-item-1759906219477-adverse-event-analytics
**type:** component
**componentType:** AdverseEventAnalytics
**description:** 
**content title:** Adverse Event Analytics
**content component:** AdverseEventAnalytics
**content props patientData adverseEvents 0 event:** Drug-Induced Liver Injury (DILI)
**content props patientData adverseEvents 0 severity:** Severe
**content props patientData adverseEvents 0 description:** Acute hepatocellular injury with jaundice and encephalopathy following TMP-SMX initiation in patient on chronic MTX
**content props patientData adverseEvents 1 event:** Hepatic Encephalopathy
**content props patientData adverseEvents 1 severity:** 4
**content props patientData adverseEvents 1 description:** Asterixis, disorientation to time/place, GCS 13 (E4 V3 M6)
**content props patientData adverseEvents 2 event:** Acute Liver Failure
**content props patientData adverseEvents 2 severity:** 4
**content props patientData adverseEvents 2 description:** ALT/AST >20× ULN, INR elevated, bilirubin ≥3× ULN with clinical jaundice
**content props patientData adverseEvents 3 event:** Methotrexate Toxicity
**content props patientData adverseEvents 3 severity:** Severe
**content props patientData adverseEvents 3 description:** Synergistic hepatotoxicity with TMP-SMX; oral mucosal ulcerations present
**content props patientData riskAssessment keyRiskFactors 0:** The patient developed acute jaundice, confusion, and hepatic tenderness shortly after initiating TMP-SMX (started June 15; symptoms June 20; presentation June 21), a timeline that strongly fits idiosyncratic hepatocellular DILI
**content props patientData riskAssessment keyRiskFactors 1:** Mechanistically, TMP-SMX can raise free methotrexate levels and impair folate metabolism; in an older patient with alcohol use (and possible CKD), this pharmacologic interaction plausibly potentiates hepatocellular necrosis
**content props patientData riskAssessment keyRiskFactors 2:** The clinical pattern is hepatocellular (expected ALT > AST ≫ ALP) and the presence of encephalopathy with presumed INR >1.5 and elevated bilirubin meets criteria for non-acetaminophen acute liver failure
**content props patientData riskAssessment keyRiskFactors 3:** RUCAM totals 7 (Probable), with TMP-SMX as the primary culprit and methotrexate as a significant co-factor
**content props patientData riskAssessment keyRiskFactors 4:** Immediate management includes withdrawal of both agents, initiation of N-acetylcysteine, aggressive supportive care, and ICU-level monitoring
**createdAt:** 2025-10-14T16:50:19.477Z
**updatedAt:** 2025-10-14T16:50:19.477Z

# Object Record 5
**objectId:** dashboard-item-1759906300004-single-encounter-6
**type:** component
**componentType:** SingleEncounterDocument
**description:** 
**content title:** Encounter #6 - Emergency Visit
**content component:** SingleEncounterDocument
**content props encounter encounter no:** 6
**content props encounter meta visit type:** ED
**content props encounter meta date time:** 2025-06-21T14:00:00
**content props encounter meta provider name:** Dr. Sarah Chen
**content props encounter meta provider specialty:** Emergency Medicine
**content props encounter meta ui risk color:** red
**content props encounter meta event tags 0:** Suspected DILI
**content props encounter meta event tags 1:** Potential MTX toxicity
**content props encounter meta event tags 2:** Acute liver failure risk
**content props encounter reason for visit:** Severe fatigue, jaundice, epigastric pain, confusion
**content props encounter chief complaint:** Severe fatigue, jaundice, epigastric pain, confusion
**content props encounter hpi:** 63-year-old female with 24h severe fatigue, jaundice, epigastric pain; 4–6 days prior noted fatigue, mouth ulcers, nausea; started TMP-SMX 6 days ago for sinusitis
**content props encounter medications prior 0 name:** Methotrexate
**content props encounter medications prior 0 dose:** 20 mg
**content props encounter medications prior 0 route:** PO
**content props encounter medications prior 0 frequency:** weekly
**content props encounter medications prior 1 name:** Trimethoprim-Sulfamethoxazole
**content props encounter medications prior 1 dose:** 800/160 mg
**content props encounter medications prior 1 route:** PO
**content props encounter medications prior 1 frequency:** BID
**content props encounter physical exam general:** Jaundiced, fatigued, drowsy; disoriented to time/place
**content props encounter physical exam abdomen:** Soft, non-distended; mild epigastric tenderness
**content props encounter physical exam cns:** Arousable; PERL; slow commands; asterixis present; GCS 13
**content props encounter assessment impression:** Acute liver injury likely DILI and/or severe methotrexate toxicity
**content props encounter assessment differential 0:** Severe methotrexate toxicity
**content props encounter assessment differential 1:** TMP-SMX–induced DILI
**content props encounter assessment differential 2:** Acute viral hepatitis
**content props encounter plan investigations labs 0:** CBC
**content props encounter plan investigations labs 1:** CMP
**content props encounter plan investigations labs 2:** Methotrexate level (urgent)
**content props encounter plan investigations labs 3:** HAV IgM
**content props encounter plan investigations labs 4:** HBsAg
**content props encounter plan management education 0:** Immediate ICU admission
**content props encounter plan management education 1:** N-acetylcysteine protocol
**content props patient name:** Sarah Miller
**content props patient sex:** Female
**content props patient age at first encounter:** 53
**content props encounterIndex:** 5
**content props dataSource:** VueExplore
**createdAt:** 2025-10-14T16:55:00.004Z
**updatedAt:** 2025-10-14T16:55:00.004Z

# Object Record 2
**objectId:** dashboard-item-1759906300004-single-encounter-3
**type:** component
**componentType:** SingleEncounterDocument
**description:** 
**content title:** Encounter #3 - Outpatient (Elevated BP)
**content component:** SingleEncounterDocument
**content props encounter encounter no:** 3
**content props encounter meta visit type:** Outpatient
**content props encounter meta date time:** 2018-09-05T10:00:00
**content props encounter meta provider name:** None
**content props encounter meta provider specialty:** General Practice
**content props encounter meta ui risk color:** green
**content props encounter reason for visit:** Routine review; elevated blood pressure
**content props encounter chief complaint:** Raised BP readings at home
**content props encounter hpi:** BP 145–155/90–95; asymptomatic. RA well-controlled on MTX 10 mg but specialist advised increase to 20 mg for mild flares. Quit smoking in 2017; continues 1–2 beers/day.
**content props encounter medications prior 0 name:** Methotrexate
**content props encounter medications prior 0 dose:** 10 mg
**content props encounter medications prior 0 route:** PO
**content props encounter medications prior 0 frequency:** weekly
**content props encounter medications prior 1 name:** Folic Acid
**content props encounter medications prior 1 dose:** 5 mg
**content props encounter medications prior 1 route:** PO
**content props encounter medications prior 1 frequency:** weekly
**content props encounter medications prior 2 name:** Paracetamol
**content props encounter medications prior 2 dose:** None
**content props encounter medications prior 2 route:** PO
**content props encounter medications prior 2 frequency:** PRN
**content props encounter physical exam general:** Well
**content props encounter physical exam vitals:** BP 148/92, HR 72, RR 16, Temp 36.8°C
**content props encounter physical exam cvs:** Normal S1/S2, no murmurs
**content props encounter physical exam msk:** No active synovitis
**content props encounter assessment impression:** New essential hypertension; RA stable; plan MTX dose increase
**content props encounter plan investigations labs 0:** CBC
**content props encounter plan investigations labs 1:** LFTs
**content props encounter plan investigations labs 2:** Creatinine
**content props encounter plan investigations labs 3:** eGFR
**content props encounter plan management medications started 0 name:** Lisinopril
**content props encounter plan management medications started 0 dose:** 10 mg
**content props encounter plan management medications started 0 route:** PO
**content props encounter plan management medications started 0 frequency:** daily
**content props encounter plan management medications started 1 name:** Methotrexate
**content props encounter plan management medications started 1 dose:** 20 mg
**content props encounter plan management medications started 1 route:** PO
**content props encounter plan management medications started 1 frequency:** weekly
**content props encounter plan management education 0:** Lisinopril side effects (e.g., cough); monitor BP regularly
**content props encounter plan management education 1:** Reinforce alcohol moderation with higher MTX dose
**content props encounter plan management education 2:** Continue Folic Acid the day after MTX
**content props patient name:** Sarah Miller
**content props patient sex:** Female
**content props patient age at first encounter:** 53
**content props encounterIndex:** 2
**content props dataSource:** Viper
**createdAt:** 2025-10-15T08:00:00.000Z
**updatedAt:** 2025-10-15T08:00:00.000Z

# Object Record 3
**objectId:** dashboard-item-1759906300004-single-encounter-4
**type:** component
**componentType:** SingleEncounterDocument
**description:** 
**content title:** Encounter #4 - Outpatient (Chronic Review)
**content component:** SingleEncounterDocument
**content props encounter encounter no:** 4
**content props encounter meta visit type:** Outpatient
**content props encounter meta date time:** 2021-03-15T09:00:00
**content props encounter meta provider name:** None
**content props encounter meta provider specialty:** General Practice
**content props encounter meta ui risk color:** green
**content props encounter reason for visit:** Routine chronic disease review (RA, HTN)
**content props encounter chief complaint:** Routine follow-up for RA/HTN
**content props encounter hpi:** Overall well; RA controlled on MTX 20 mg; BP controlled on Lisinopril; occasional low back pain; eGFR mildly declined but stable; continues 1–2 beers/day.
**content props encounter medications prior 0 name:** Methotrexate
**content props encounter medications prior 0 dose:** 20 mg
**content props encounter medications prior 0 route:** PO
**content props encounter medications prior 0 frequency:** weekly
**content props encounter medications prior 1 name:** Folic Acid
**content props encounter medications prior 1 dose:** 5 mg
**content props encounter medications prior 1 route:** PO
**content props encounter medications prior 1 frequency:** weekly (next day after MTX)
**content props encounter medications prior 2 name:** Lisinopril
**content props encounter medications prior 2 dose:** 10 mg
**content props encounter medications prior 2 route:** PO
**content props encounter medications prior 2 frequency:** daily
**content props encounter medications prior 3 name:** Paracetamol
**content props encounter medications prior 3 dose:** None
**content props encounter medications prior 3 route:** PO
**content props encounter medications prior 3 frequency:** PRN
**content props encounter physical exam general:** Fit/well
**content props encounter physical exam vitals:** BP 130/82, HR 68, RR 16, Temp 36.7°C
**content props encounter physical exam msk:** No synovitis
**content props encounter physical exam abdomen:** Soft, non-tender
**content props encounter assessment impression:** Stable RA; controlled HTN; chronic mild low back pain; mild CKD (stable)
**content props encounter plan investigations labs 0:** CBC
**content props encounter plan investigations labs 1:** LFTs
**content props encounter plan investigations labs 2:** Creatinine
**content props encounter plan investigations labs 3:** eGFR
**content props encounter plan management education 0:** Continue MTX 20 mg weekly, Folic Acid 5 mg weekly, Lisinopril 10 mg daily
**content props encounter plan management education 1:** Hydration importance with CKD and ACE inhibitor
**content props encounter plan management education 2:** Alcohol moderation reinforced
**content props patient name:** Sarah Miller
**content props patient sex:** Female
**content props patient age at first encounter:** 53
**content props encounterIndex:** 3
**content props dataSource:** ICE
**createdAt:** 2025-10-15T08:00:00.000Z
**updatedAt:** 2025-10-15T08:00:00.000Z